Are you Dr. Javle?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 33 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Summary
- Dr. Milind Javle, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
- University at BuffaloFellowship, Hematology and Medical Oncology, 1995 - 1998
- University at BuffaloResidency, Internal Medicine, 1993 - 1994
- Grant Medical CollegeClass of 1991
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2007 - 2024
- OK State Medical License 2020 - 2021
- NY State Medical License 1998 - 2007
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer Start of enrollment: 2002 Jan 01
- Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Start of enrollment: 2002 Oct 01
- Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer Start of enrollment: 2003 May 01
- Join now to see all
Publications & Presentations
PubMed
- ASO Visual Abstract: Revisiting the Malignant Masquerade at the Liver Hilum-Have We Made Progress?Jain, A., Lendoire, M., Cao, H., Hu, Z., Boyev, A., Newhook, T., Tzeng, C., Coronel, E., Lee, S., Javle, M., Lee, J., Vauthey, J., Chun, Y.> ;Annals of Surgical Oncology. 2024 Feb 21
- Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.DiPeri, T., Evans, K., Wang, B., Zhao, M., Akcakanat, A., Raso, M., Rizvi, Y., Zheng, X., Korkut, A., Varadarajan, K., Uzunparmak, B., Dumbrava, E., Pant, S., Ajani, J...> ;Cancer Discovery. 2024 Feb 15
- Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.Ngoi, N., Tang, T., Gaspar, C., Pavlick, D., Buchold, G., Scholefield, E., Parimi, V., Huang, R., Janovitz, T., Danziger, N., Levy, M., Pant, S., De Armas, A., Kumpula...> ;The Oncologist. 2024 Feb 8
- Join now to see all
Authored Content
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
- Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
Press Mentions
- MD Anderson Research Highlights for August 11, 2021August 11th, 2021
- The 4th OrigiMed International Summit Held in ShanghaiJune 8th, 2021
- GSK, German Merck's $4.2B Bintrafusp Alfa Drug Flops Again, but Companies Squint to See Glimmers of HopeMarch 16th, 2021
- Join now to see all
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas